[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.171.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Editor's Correspondence
Oct 10, 2011

Cardiovascular Device Technology and Health Care Cost—Reply

Author Affiliations

Author Affiliation: Department of Medicine, University of California, San Francisco.

Arch Intern Med. 2011;171(18):1689. doi:10.1001/archinternmed.2011.465

In reply

I agree with Dr Dean's statement that the “application of therapy should be based on the evidence.” That is why it is disappointing that he refers to the “life-saving properties” of DESs without offering support for this statement. Indeed, significant mortality benefits have not been seen with DESs.1 The end point used in almost all large, high-quality randomized controlled trials on this subject is a composite outcome, largely driven by decreased need for revascularization.

First Page Preview View Large
First page PDF preview
First page PDF preview
×